Prognostic value of DNA ploidy: 5-year follow-up of patients with resectable squamous cell carcinoma (SCC) of the lung

Kasprzyk, Mariusz; Dyszkiewicz, Wojciech; Piwkowski, Cezary; Gąsiorowski, Łukasz; Kaczmarek, Elżbieta

doi:10.1016/j.lungcan.2005.10.014

Cited by 11 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumour samples analysed demonstrated substantial genomic instability, with comparisons between subgroups failing to demonstrate any significant difference. Previous studies of copy number changes in NSCLC have found no association between age, gender, histology, stage or tumour grade and the degree of genomic instability [19-21]. The absence of difference in the degree of genomic abnormalities between KRAS mutant and wt tumours is interesting, as both our transcriptional and genomic data imply enhanced activity of genes involved in chromosome structure and organisation in KRAS mutant tumours.…”

Section: Discussionmentioning

confidence: 45%

Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer

et al. 2011

View full text Add to dashboard Cite

BackgroundThe aim of this study was to identify critical genes involved in non-small cell lung cancer (NSCLC) pathogenesis that may lead to a more complete understanding of this disease and identify novel molecular targets for use in the development of more effective therapies.MethodsBoth transcriptional and genomic profiling were performed on 69 resected NSCLC specimens and results correlated with mutational analyses and clinical data to identify genetic alterations associated with groups of interest.ResultsCombined analyses identified specific patterns of genetic alteration associated with adenocarcinoma vs. squamous differentiation; KRAS mutation; TP53 mutation, metastatic potential and disease recurrence and survival. Amplification of 3q was associated with mutations in TP53 in adenocarcinoma. A prognostic signature for disease recurrence, reflecting KRAS pathway activation, was validated in an independent test set.ConclusionsThese results may provide the first steps in identifying new predictive biomarkers and targets for novel therapies, thus improving outcomes for patients with this deadly disease.

show abstract

Section: Discussionmentioning

confidence: 45%

Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The first reports on the prognostic significance of aneuploidy (abnormal amount of DNA) in lung cancer date from the late 1980s [1][2][3][4]. The relatively few reports that have appeared since then are quite inconsistent as to the prognostic significance of ploidy [5][6][7][8][9] This research is a continuation of studies, the early results of which were published in 2000 and 2005 [10,11] The current focus is on the analysis of the effect of aneuploidy on 10-year survival rates in the group of patients treated surgically for squamous cell lung cancer.…”

Section: Introductionmentioning

confidence: 99%

TORAKOCHIRURGIA DNA ploidy as an independent prognostic factor: 10-year results in a group of patients surgically treated for squamous cell lung cancer

Kasprzyk¹,

Dyszkiewicz²,

Roszak³

et al. 2012

kitp

Self Cite

View full text Add to dashboard Cite

StreszczenieWstęp: Duża zmienność biologiczna raka płuca powoduje, że mimo określonego typu histologicznego i stopnia zaawansowania raka wg klasyfikacji TNM przebieg choroby jest trudny do przewidzenia. Dlatego poszukuje się molekularnych i biochemicznych czynników mających znaczenie prognostyczne i pomocnych w kwalifikacji chorych do pooperacyjnej chemioterapii. Jednym z takich czynników mogą być zaburzenia zawartości DNA w komórkach nowotworowych, choć opinie na temat rokowniczego znaczenia ploidii są wśród badaczy podzielone. Celem pracy była ocena wpływu nieprawidłowej ilości DNA w komórkach raka na wyniki odległe (10-letnie) leczenia chirurgicznego raka płaskonabłonkowego płuca. Materiał i metody: Analizie poddano grupę 110 chorych leczonych operacyjnie z powodu raka płaskonabłonkowego płuca w latach 1995-1997. W badanej grupie było 95 mężczyzn i 15 kobiet w wieku 34-77 lat (średnia 60 lat). U 52 chorych wykonano lobektomię, u 47 pneumonektomię, a u 11 inne resekcje. Większość chorych operowano w stadium IB (35 chorych), IIB (26 pacjentów) i IIIA (22 chorych). Badany materiał stanowiły preparaty parafinowe, w których metodą cytometrii przepły-wowej zbadano zawartość DNA w komórkach raka. W każdym przypadku oznaczono indeks DNA, a ilość DNA w komórkach nowotworowych zilustrowano w postaci histogramów. Analizę statystyczną przeprowadzono przy użyciu program komputerowy Statistica 10.0 i oraz StatXact 8. Wyniki: Odsetek przypadków aneuploidalnych (z nieprawidło-wą ilością DNA) wyniósł 44,5%. Nie stwierdzono korelacji mię- AbstractBackground: The biological variability of lung cancer is one of the causes of the unpredictable clinical outcome of the disease. Many investigators have devoted a lot of effort to finding molecular and biochemical prognostic factors that may prove helpful in the qualification of patients for postoperative chemotherapy. Notwithstanding various previous studies attempted to associate DNA quantification in cancer cells with the prognosis for lung cancer, there is a divergence of opinion about its value. The aim of the present study was to assess the impact of aneuploidy on late (10-year) survival in a group of patients treated surgically for squamous cell lung cancer. Material and methods: We analyzed a group of 110 patients surgically treated for squamous cell lung cancer between 1995 and 1997. The group consisted of 95 men and 15 women, aged between 34 and 77 years (the average age being 60). We performed lobectomy in 52 cases, pneumonectomy in 47 cases, and other resections in 11 patients. Most of the patients were in IB (35 cases), IIB (26 patients) and IIIA (22 cases

show abstract

“…Flow cytometric (FC) DNA content (DNA ploidy) evaluation is widely used tool in the prognostication of many solid tumors as well as hematological malignancies . It is an easy and rapid method to study the DNA content in the cells and to estimate proportion of cells present in different phases of the cell cycle.…”

mentioning

confidence: 99%

A novel and easy FxCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six‐color immunophenotyping

et al. 2015

View full text Add to dashboard Cite

Abnormal DNA ploidy is a valuable prognostic factor in many neoplasms, especially in hematological neoplasms like B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). Current methods of flow-cytometric (FC) DNA-ploidy evaluation are either technically difficult or limited to three-to four-color immunophenotyping and hence, challenging to evaluate DNA-ploidy in minute tumor population with background rich of its normal counterpart cells and other hematopoietic cells. We standardized a novel sensitive and easy method of simultaneous evaluation of six-to sevencolor immunophenotyping and DNA-ploidy using a dye-FxCycle Violet (FCV). Linearity, resolution, and coefficient of variation (CV) for FCV were studied using chicken erythrocyte nuclei. Ploidy results of FCV were compared with Propidium iodide (PI) in 20 samples and intra-assay variation for FCV was studied. Using this six-color immunophenotyping & FCV-protocol DNA-ploidy was determined in bone-marrow samples from 124 B-ALL & 50 MM patients. Dilution experiment was also conducted to determine the sensitivity in detection of aneuploidy in minute tumor population. FCV revealed high linearity and resolution in 450/50 channel. On comparison with PI, CV of Go/G1-peak with FCV (mean-CV 4.1%) was slightly higher than PI (mean-CV 2.9%) but had complete agreement in ploidy results. Dilution experiment showed that aneuploidy could be accurately detected up to the limit of 0.01% tumor cells. Intraassay variation was very low with CV of 0.005%. In B-ALL, hypodiploidy was noted in 4%, hyperdiploidy in 24%, near-hyperdiploidy in 13% and remaining 59% were diploid. In MM, hypodiploidy was in 2%, hyperdiploidy in 58%, near-hyperdiploidy in 8% and remaining 30% were diploid. FCV-based DNA-ploidy method is a sensitive and easy method for simultaneous evaluation of six-color immunophenotyping and DNA analysis. It is useful in DNA-ploidy evaluation of minute tumor population in cases like minimal residual disease and MM precursor conditions. V C 2015 International Society for Advancement of CytometryKey terms DNA ploidy; cell cycle; FxCycle-violet; simultaneous multicolor immunophenotyping FLOW cytometric (FC) DNA content (DNA ploidy) evaluation is widely used tool in the prognostication of many solid tumors as well as hematological malignancies (1-5). It is an easy and rapid method to study the DNA content in the cells and to estimate proportion of cells present in different phases of the cell cycle. FC DNA ploidy analysis includes estimation of DNA index (DI) calculated by ratio of mean fluorescence of "G0/G1" peak of tumor cells to normal lymphocytes that reveals change in amount of DNA content of tumor cells in relation to normal diploid cells and percentage "S" phase provides an objective estimation of cell growth and may

show abstract

Prognostic value of DNA ploidy: 5-year follow-up of patients with resectable squamous cell carcinoma (SCC) of the lung

Cited by 11 publications

References 21 publications

Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer

Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer

TORAKOCHIRURGIA DNA ploidy as an independent prognostic factor: 10-year results in a group of patients surgically treated for squamous cell lung cancer

A novel and easy FxCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six‐color immunophenotyping

Contact Info

Product

Resources

About